IRVINE, CA / ACCESS Newswire / October 16, 2025 / PRO-DEX, INC. (NasdaqCM:PDEX) is issuing this press release in an effort to help avoid any confusion in the marketplace between the common stock of Pro-Dex, Inc., which trades on the Nasdaq Capital Market under the symbol PDEX, and Polkadex, which to Pro-Dex, Inc.'s understanding trades on certain crypto exchanges (and possibly on certain other platforms) under the same symbol. There is no relationship or affiliation between Pro-Dex, Inc. and Polkadex. Given that both Pro-Dex, Inc. and Polkadex are associated with the PDEX symbol, investors are encouraged to carefully inquire as to any research or trading involving the PDEX symbol to ensure that any such research or trade accurately reflects the investor's intent as between Pro-Dex, Inc. or Polkadex.
About Pro-Dex, Inc.
Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery-powered, and electric multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. We have patented adoptive torque-limiting software and proprietary sealing solutions which appeal to our customers, primarily medical device distributors. Pro-Dex also sells rotary air motors, however, these motors represent a de minimis portion of total revenue. Pro-Dex's products are found in hospitals and medical engineering labs around the world. For more information, visit the Company's website at www.pro-dex.com.
Contact:
Richard L. Van Kirk, Chief Executive Officer
(949) 769-3200
| Last Trade: | US$36.24 |
| Daily Change: | 5.61 18.32 |
| Daily Volume: | 142,304 |
| Market Cap: | US$118.870M |
October 30, 2025 September 04, 2025 September 05, 2024 November 02, 2023 | |

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load